Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) EVP Ourania Tatsis sold 2,350 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $439.11, for a total value of $1,031,908.50. Following the completion of the transaction, the executive vice president now directly owns 53,523 shares in the company, valued at $23,502,484.53. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Vertex Pharmaceuticals Stock Up 3.3 %
Shares of Vertex Pharmaceuticals stock opened at $470.18 on Tuesday. The company has a quick ratio of 3.29, a current ratio of 3.50 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a 12-month low of $323.02 and a 12-month high of $471.39. The firm has a market capitalization of $121.33 billion, a PE ratio of 30.51, a price-to-earnings-growth ratio of 2.34 and a beta of 0.41. The stock's fifty day moving average is $418.03 and its 200-day moving average is $410.73.
AI's Next Magnificent Seven
From The Oxford Club | Ad
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
See His Breakdown of the Seven Stocks You Should Own Here.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, topping the consensus estimate of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The company had revenue of $2.69 billion during the quarter, compared to analysts' expectations of $2.58 billion. During the same period last year, the company posted $2.67 earnings per share. The business's revenue for the quarter was up 13.3% on a year-over-year basis. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.22 earnings per share for the current year.
Analysts Set New Price Targets
Several analysts have issued reports on the company. BMO Capital Markets upped their price objective on Vertex Pharmaceuticals from $480.00 to $500.00 and gave the company an "outperform" rating in a research note on Friday. Royal Bank of Canada increased their target price on shares of Vertex Pharmaceuticals from $417.00 to $424.00 and gave the stock a "sector perform" rating in a report on Tuesday, May 7th. William Blair reissued an "outperform" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 6th. Cantor Fitzgerald reissued an "overweight" rating and issued a $440.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, February 20th. Finally, Oppenheimer reissued an "outperform" rating and set a $500.00 price target on shares of Vertex Pharmaceuticals in a report on Monday, April 15th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $438.62.
View Our Latest Report on VRTX
Institutional Trading of Vertex Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the business. University of Texas Texas AM Investment Managment Co. purchased a new stake in Vertex Pharmaceuticals in the 4th quarter worth about $25,000. Annapolis Financial Services LLC acquired a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at about $27,000. Arlington Trust Co LLC lifted its position in shares of Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 33 shares in the last quarter. ICA Group Wealth Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth approximately $28,000. Finally, Fortitude Family Office LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $30,000. Institutional investors and hedge funds own 90.96% of the company's stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- How to Start Investing in Real Estate
- Why Smartsheet Stock is an Undervalued Gem of an Investment
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- The Most Upgraded Stocks After the Q1 Earnings Season
- Dividend Payout Ratio Calculator
- What Is Risk Tolerance & Why Is It Important?
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [emailprotected].
Insider Buying or Selling at Vertex Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Vertex Pharmaceuticals and related companies.
More From MarketBeat
